% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Fischer:272592,
      author       = {Fischer, Thomas and Dietlein, Felix and Bongartz, Detlev
                      and Klehr, Martin and Zimmermanns, Beate and Schmidt,
                      Matthias and Mohr, Angela and Mohr, Fabian and Sudbrock,
                      Ferdinand and Krapf, Philipp and Drzezga, Alexander and
                      Dietlein, Markus and Schomäcker, Klaus},
      title        = {{T}umoricidal {A}ctivity and {S}ide {E}ffects of
                      {R}adiolabeled {A}nti-{NCAM} [131{I}]-{I}odine-{ERIC}1 in
                      {N}euroblastoma-{B}earing {M}ice},
      journal      = {International journal of molecular sciences},
      volume       = {25},
      number       = {19},
      issn         = {1422-0067},
      address      = {Basel},
      publisher    = {Molecular Diversity Preservation International},
      reportid     = {DZNE-2024-01213},
      pages        = {10737},
      year         = {2024},
      abstract     = {Preliminary studies on a radioactive antibody against the
                      neural cell adhesion molecule (NCAM) demonstrated a
                      significant accumulation of [131I]I-ERIC1 in neuroblastoma
                      tumor cells in mice. This study aims to validate the
                      therapeutic efficacy and potential adverse effects of these
                      radioactive immunoconjugates (RICs) in neuroblastoma-bearing
                      mice. To determine the highest tolerated dose, healthy SCID
                      mice received 1 to 22 MBq of [131I]I-ERIC1, with the
                      survival time measured. Tumor response was evaluated by
                      administering 0.8 to 22 MBq of [131I]I-ERIC1 to
                      neuroblastoma-bearing mice and assessing tumor size and
                      systemic toxicity through body weight, blood counts, and
                      survival. It was observed that doses up to approximately 3
                      MBq per animal (150 MBq/kg) were well tolerated, whereas
                      higher doses resulted in systemic toxicity and death. The
                      neuroblastomas exhibited a dose-dependent response, with
                      optimal therapeutic efficacy achieved at 1.8-2.5 MBq per
                      animal (90-125 MBq/kg), significantly extending survival by
                      a factor of five. The antibody ERIC1 is a promising vehicle
                      for the transport of beta emitters into NCAM-positive tumor
                      tissue. An optimal dosage of the [131I]I-ERIC1 antibody can
                      be established with a balance of tumor-static effects and
                      adverse effects, resulting in a marked extension of survival
                      time.},
      keywords     = {Animals / Neuroblastoma: pathology / Neuroblastoma:
                      metabolism / Neuroblastoma: drug therapy / Mice / Iodine
                      Radioisotopes: adverse effects / Cell Line, Tumor / Neural
                      Cell Adhesion Molecules: metabolism / Humans / Mice, SCID /
                      Xenograft Model Antitumor Assays / Immunoconjugates:
                      pharmacology / Female / Antibodies, Monoclonal: therapeutic
                      use / Antibodies, Monoclonal: pharmacology},
      cin          = {AG Boecker},
      ddc          = {540},
      cid          = {I:(DE-2719)1011202},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39409066},
      pmc          = {pmc:PMC11476365},
      doi          = {10.3390/ijms251910737},
      url          = {https://pub.dzne.de/record/272592},
}